A detailed history of Bard Financial Services, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bard Financial Services, Inc. holds 255 shares of REGN stock, worth $294,083. This represents 0.03% of its overall portfolio holdings.

Number of Shares
255
Previous 280 8.93%
Holding current value
$294,083
Previous $269,000 0.37%
% of portfolio
0.03%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 09, 2024

SELL
$883.2 - $1071.19 $22,080 - $26,779
-25 Reduced 8.93%
255 $268,000
Q3 2023

Oct 16, 2023

SELL
$692.45 - $844.37 $31,160 - $37,996
-45 Reduced 13.85%
280 $230,000
Q1 2023

Apr 26, 2023

SELL
$680.49 - $826.97 $17,012 - $20,674
-25 Reduced 7.14%
325 $267,000
Q4 2022

Jan 25, 2023

SELL
$705.89 - $766.39 $35,294 - $38,319
-50 Reduced 12.5%
350 $253,000
Q2 2021

Jul 13, 2021

BUY
$472.8 - $558.54 $189,120 - $223,416
400 New
400 $223,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $124B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Bard Financial Services, Inc. Portfolio

Follow Bard Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bard Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bard Financial Services, Inc. with notifications on news.